Halozyme Therapeutics, Inc. (HALO) News

Halozyme Therapeutics, Inc. (HALO): $46.75

0.42 (+0.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HALO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter HALO News Items

HALO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HALO News Highlights

  • For HALO, its 30 day story count is now at 17.
  • Over the past 23 days, the trend for HALO's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • The most mentioned tickers in articles about HALO are BEAT, SUN and MS.

Latest HALO News From Around the Web

Below are the latest news stories about Halozyme Therapeutics Inc that investors may wish to consider to help them evaluate HALO as an investment opportunity.

Halozyme''s Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline Growth

Halozyme Therapeutics Inc (NASDAQ: HALO ) reported Q4 revenue of $102 million compared to $121.7 million a year ago, beating the consensus of $100.32 million. The decrease was primarily driven by a decline in revenue under collaboration agreement and product sales, partially offset by an increase in royalty revenue attributable to subcutaneous Darzalex (daratumumab). Revenue for Q4 included $62.6 million in royalties. Adjusted EPS of $0.42 beat Full story available on Benzinga.com

Benzinga | February 23, 2022

Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues

Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.

Yahoo | February 23, 2022

Halozyme Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 22, 2022

Halozyme Therapeutics, Inc.''s (HALO) CEO Helen Torley On Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 22, 2022

Halozyme Therapeutics Non-GAAP EPS of $0.42 beats by $0.01, revenue of $102M beats by $2.31M

Halozyme Therapeutics press release (HALO): Q4 Non-GAAP EPS of $0.42 beats by $0.01.Revenue of $102M (-16.2% Y/Y) beats by $2.31M.2022 Revenue Guidance of $530 to $560

Seeking Alpha | February 22, 2022

Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 22, 2022

HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on its recent corporate activities and outlook.

Yahoo | February 22, 2022

Halozyme Therapeutics Q4 2021 Earnings Preview

Halozyme Therapeutics (NASDAQ:HALO) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, after market close. The consensus EPS Estimate is $0.41 and the consensus Revenue Estimate is $99.69M (-18.1% Y/Y). Over the last 2 years, HALO has beaten EPS estimates 50% of the time and has beaten revenue...

Seeking Alpha | February 21, 2022

Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 15, 2022

HALOZYME TO HOST FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2021 on Tuesday, February 22 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the fourth quarter and year ended December 31, 2021, following the close of trading.

Yahoo | February 9, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4982 seconds.